Fingolimod was the first oral disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis (MS). It has previously been associated with rare cases of lymphoma. Here we describe the first case of mycosis fungoides - a cutaneous lymphoproliferative disorder, in an MS patient treated with fingolimod. who developed histologically confirmed mycosis fungoides 3 years after starting fingolimod. The drug was withdrawn and the patient was treated with radiotherapy and surgical excision with remission. This report points to a possible association between fingolimod and skin lymphoproliferative disorder and emphasizes the need for periodic skin examination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocn.2017.10.077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-high-frequency Ultrasound in the Objective Assessment of Chlormethine Gel Efficacy: A Case Report.
Acta Dermatovenerol Croat
November 2024
Agata Janowska, MD, Department of Dermatology, , University of Pisa, Via Roma 67, 56126, Pisa, Italy; Phone: +39 050 992436, Fax: +39 050 992556,
Mycosis fungoides (MF) represent the most frequent form of cutaneous T-cell lymphoma (CTCL). Chlormethine gel has been approved as first-line therapy in MF. The classification of early forms of MF is clinically and histologically complex even for experienced clinicians.
View Article and Find Full Text PDFAdvances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
Curr Hematol Malig Rep
January 2025
Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
Article Synopsis
- Cutaneous T cell lymphomas (CTCLs) are challenging to treat non-Hodgkin lymphomas, with Mycosis fungoides (MF) and Sezary syndrome (SS) being the most prevalent subtypes.
- There is no established standard treatment or cure for these conditions, making management difficult.
- Recent clinical trials are testing new therapies, including innovative chemotherapies, antibodies, immunotherapies, and cellular therapies that could enhance treatment options for MF and SS.
Could Residents Adequately Assess the Severity of Skin Lesions in Mycosis Fungoides/Sézary Syndrome? Evaluation of Interrater Agreement and Interrater Reliability of mSWAT.
J Clin Med
December 2024
Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Article Synopsis
- Cutaneous T-cell lymphoma (CTCL) is a complex skin cancer that includes Mycosis fungoides and Sézary syndrome, making accurate diagnosis and severity assessment essential for effective treatment.
- A study involving 16 dermatology residents showed significant variability in their evaluation of lesions using the mSWAT scoring system, particularly with tumors and lesions in erythrodermic patients, which were often misclassified.
- The findings reveal the need for better training and standardized protocols in scoring to enhance reliability in assessing CTCL severity, similar to other assessment tools in dermatology.
Correction: Häyrinen et al. The Transcription Factor Twist1 Has a Significant Role in Mycosis Fungoides (MF) Cell Biology: An RNA Sequencing Study of 40 MF Cases. 2023, , 1527.
Cancers (Basel)
January 2025
Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
In the original publication [...
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!